Matsuda Masaru — SEC Form 4 filings
SEC reporting owner CIK 1798679. 24 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2024-01-17 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 5,657 shares, $18,543 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 30 legs across 21 filings — 170,712 shares, $3,341,445 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 36,130 shares @ $16.16 ($583,716) in Arcutis Biotherapeutics, Inc., filed 2025-09-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | See Remarks | 24 | 2 legs · 5,657 sh · $18,543 | 30 legs · 170,712 sh · $3,341,445 | 14 |
Form 4 filings — Matsuda Masaru
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 3,674 @ $25.00 | EDGAR |
| 2026-09-10 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 9,989 @ $25.03 | EDGAR |
| 2026-08-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 1,230 @ $26.12 | EDGAR |
| 2026-05-06 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 7,372 @ $23.27 · Sale (S): 884 @ $23.61 | EDGAR |
| 2026-03-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 37,000 @ $0 · Sale (S): 3,325 @ $27.95 · Sale (S): 6,553 @ $25.16 · Sale (S): 193 @ $25.91 · Sale (S): 1,987 @ $25.70 · Grant/award (A): 97,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 7,983 @ $25.50 · Sale (S): 8,562 @ $24.97 · Sale (S): 19,379 @ $25.24 · Sale (S): 4,714 @ $25.63 | EDGAR |
| 2025-12-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 1,657 @ $30.23 | EDGAR |
| 2025-11-21 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 989 @ $27.95 · Sale (S): 1,561 @ $28.50 | EDGAR |
| 2025-11-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 7,165 @ $24.71 · Sale (S): 43 @ $25.40 | EDGAR |
| 2025-09-08 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 36,130 @ $16.16 | EDGAR |
| 2025-08-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 6,330 @ $14.33 | EDGAR |
| 2025-05-29 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 1,800 @ $13.78 | EDGAR |
| 2025-05-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 5,030 @ $15.20 | EDGAR |
| 2025-03-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 34,000 @ $0 · Sale (S): 3,263 @ $13.03 · Grant/award (A): 89,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 8,338 @ $12.70 | EDGAR |
| 2024-12-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Purchase (P): 4,000 @ $1.69 · Purchase (P): 1,657 @ $7.11 | EDGAR |
| 2024-11-19 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 4,875 @ $0 · Sale (S): 1,775 @ $9.68 | EDGAR |
| 2024-11-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 5,015 @ $8.68 | EDGAR |
| 2024-08-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 5,220 @ $9.02 | EDGAR |
| 2024-05-29 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 4,875 @ $0 · Sale (S): 1,775 @ $9.01 | EDGAR |
| 2024-05-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 5,016 @ $8.74 | EDGAR |
| 2024-03-06 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 3,760 @ $11.12 | EDGAR |
| 2024-02-15 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 74,000 · Grant/award (A): 17,650 · Grant/award (A): 27,900 · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 35,300 (derivative) · Disposition to issuer (D): 55,800 (derivative) | EDGAR |
| 2024-01-17 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 28,000 @ $0 · Grant/award (A): 176,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1798679 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →